Liminatus Pharma LIMN
NASDAQ LIMN
$3.88 +0.13 (+3.47%)
As of: Oct 2, 2026 · 11:13 AM EDT

Liminatus Pharma (LIMN) Return on Assets [ROA] (2025 - 2026)

Updated

Liminatus Pharma's Return on Assets [ROA] came in at -133.70% for Q2 2026, up 102.39 percentage points from the prior quarter.

Analysis

Liminatus Pharma (LIMN) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Liminatus Pharma's Return on Assets [ROA] was -104.94%.

  • Business Quant data shows LIMN's Return on Assets [ROA] at -236.09% (Q1 2026), -334.96% (Q4 2025) and -149.71% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 10.47%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 4.65%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 2.45%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 28.37%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 9.10%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 9.29%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -6.13%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 2.14%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 16.34%
10 Liminatus Pharma 4.18 Mn 4.18 Mn - -133.70%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -133.70%
Mar 31, 2026 -236.09%
Dec 31, 2025 -334.96%
Sep 30, 2025 -149.71%
API Access

Liminatus Pharma Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=LIMN&period=max&api_key=YOUR_API_KEY